Aaron Christensen-Quick, Ph.D.

Aaron Christensen-Quick, Ph.D. has a wealth of experience in the fields of science and research. Aaron began their career in 2004 as an Undergraduate Researcher at the University of Minnesota, where they studied the molecular mechanisms responsible for the generation of genetic diversity in Candida albicans. Aaron also served as an Orientation Leader and Teaching Assistant during their time at the University. In 2005, they worked as a Direct Care Assistant at Dakota Communities, providing direct support to people with physical and developmental disabilities. From 2009 to 2015, they were a Graduate Research Assistant and Postdoctoral Fellow at the University of Maryland - Institute of Human Virology and the University of California San Diego, respectively. Here, they managed a project investigating the use of standard clinical vaccines as a tool to reawaken and purge the HIV reservoir. In 2018, they joined BPS Bioscience Inc. as a Senior Scientist, where they independently developed a protocol to produce CAR-T cells that demonstrate specific activation and killing of target cells. Aaron also expanded their immunotherapy portfolio by producing new lentiviral and primary human cell products, modified cancer cell lines, and cell culture media products. In 2020, they became a Scientist at Inovio Pharmaceuticals Inc. and in 2021, they were a Senior Scientist at Basilard BioTech, Inc. Aaron currently holds the position of Senior Scientist at both NanoCellect Biomedical, Inc. and Sequoia Biotech.

Aaron Christensen-Quick, Ph.D. obtained their Doctor of Philosophy (PhD) in Molecular Microbiology and Immunology from the University of Maryland Baltimore in 2015. Aaron also obtained a Bachelor of Science (BS) in Cell/Cellular and Molecular Biology from the University of Minnesota in 2007.